ASH 2024 – Merck treads a fine line in ROR1
Phase 2 data show why Merck took the lowest dose of zilo-V into phase 3.
ASH 2024 – Sumitomo joins the menin party
Enzomenib might be the most promising agent so far, on a cross-trial basis.
ASH 2024 – J&J mounts its first-line menin challenge
The group presents data with bleximenib plus chemo, but looks behind Kura’s contender.
ASH 2024 – AbbVie fights to rise above the BCMA crowd
Etentamig is one of several anti-BCMA T-cell engagers seeking attention at ASH.
Incyte hopes to sneak Zynyz through the back door
In first-line NSCLC the drug beats chemo, and not Keytruda.
ASH 2024 – Miltenyi throws its hat into the fast-Car ring
And the company might one day follow Galapagos into decentralised manufacturing.
ASH 2024 – Galapagos turns Car-T manufacturing on its head
The group claims a seven-day vein-to-vein time is unique, and says why this matters.
A fourth challenger from DualityBio and BioNTech
Yet more data validate B7-H3, and put MediLink in the deal-making frame.
Protara could take on J&J
The company’s TARA-002 produces competitive results in BCG-unresponsive bladder cancer, albeit in just five patients.
Janux impresses again
The company reports an “unprecedented” 100% PSA50 rate with JANX007, but in a small, selected number of patients.
